New evidence links dementia to problems with the brain's waste clearance system
A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...
Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ...
Positive Report for Erasca (ERAS) from Bank of America Securities
Bank of America Securities analyst Alec Stranahan upgraded Erasca (ERAS – Research Report) to a Buy today and set a price target of $5.00. The ...
Exploring IL-8⁺ neutrophils and their role in severe alcohol-associated hepatitis
Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated ...
bovnews5d
A Big Leap Forward: Verastem Oncology’s (VSTM) Stock Skyrockets Amid Breakthrough Cancer News
When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Hosted on MSN5d
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...
Verastem: NDA Acceptance Puts Key Goals In Sight
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...